NantKwest (NK) IPO Prices at $25, Above Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Wall St set for lower open as oil prices jump, earnings in focus
- Brent hits five-month high as attacks on ships, Saudi sites fuel supply worries
- Loop Capital downgrades Apple, sees no recovery of cut iPhone shipments
- Wells Fargo says S&P 500 buy signal emerges as investors turn excessively bearish
- ByteDance, Alibaba and Tencent order $35 billion of Nvidia chips: Reuters
- Cerebras Systems falls as TD Cowen cuts price target
- Nasdaq climbs as chip and AI-linked stocks bounce back
- 3M issues warrant to Amazon in $6B data center product deal
- Flutter Entertainment to cut up to 1,400 jobs amid UK tax increases
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
NantKwest (NK) Gains for Second Session Following Strong IPO
July 29, 2015 11:28 AM EDTNantKwest (Nasdaq: NK) is trading higher for the second session following Tuesday's robust IPO.
Shares of NantKwest are up well over 4 percent. Action comes as NantKwest priced its 8.28 million common stock IPO at $25 per share and opened at $37 yesterday. Shares ended up 38.6 percent higher.
... MoreNantKwest (NK) IPO Opens Up 48%
July 28, 2015 10:38 AM EDTToday's IPO for NantKwest (NASDAQ: NK) opened for trading at $37 after pricing 8,288,000 shares of its common stock at a price to the public of $25 per share, above the expected $20-$23 range. The offering size was raised from 7,000,000 shares.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.
NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat... More



